{
  "symbol": "LAB",
  "company_name": "Standard Biotools Inc",
  "ir_website": "https://investors.standardbio.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Standard BioTools Expands SomaScan Offering with Advanced Antibody Profiling",
          "url": "https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-expands-somascan-offering-advanced-antibody",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[Skip to Content](#skip-to-content)\n\n[![logo](/sites/g/files/knoqqb88461/themes/site/nir_pid1741/dist/images/logo-10-22.png)](https://www.standardbio.com/)\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News & Events](/press-releases)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/quarterly-results)\n    * [Quarterly Results](/financial-information/quarterly-results)\n    * [Annual Reports](/annual-reports)\n    * [SEC Filings](/sec-filings)\n  * [Stock Information](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Investment Calculator](/stock-information/investment-calculator)\n    * [Analyst Coverage](/analyst-coverage)\n    * [Key Ratios](/key-ratios)\n  * [Governance](/corporate-governance/governance-overview)\n    * [Governance Overview](/corporate-governance/governance-overview)\n    * [Management](https://www.standardbio.com/about/management)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Committee Composition](/corporate-governance/committeecomposition)\n    * [Contact the Board](/corporate-governance/contact-bod)\n    * [Social Responsibility](/social-responsibility)\n  * [Investor Resources](/investor-faqs)\n    * [Investor FAQs](/investor-faqs)\n    * [Investor Kit](/investor-kit-0)\n    * [Contact Us](/contact-investor)\n    * [Email Alerts](/email-alerts)\n\n\n\n# News Release Details\n\n# \n\nStandard BioTools Expands SomaScan Offering with Advanced Antibody Profiling\n\nNov 21, 2024\n\n[PDF Version](/node/19731/pdf)\n\n_The KREX_ ™ _offering provides additional high plex proteomic solutions for biopharma and_ _translational research end markets_\n\nSOUTH SAN FRANCISCO, Calif. November 21, 2024 -- Standard BioTools Inc. (Nasdaq: LAB) (\"Standard BioTools\" or the \"Company\") today announced the addition of KREX™ precision antibody profiling services and kits to its SomaScan™ suite of solutions. The expanded offering enables the detection of autoantibody biomarkers and protein interactions for basic, translational and clinical research.\n\nThis expanded offering strengthens Standard BioTools' proteomics portfolio, particularly in biopharma and translational research, by combining the proprietary immunoproteomic technology with its market leading SomaScan platform Available as an end-to-end lab service or kit, the KREX™ technology empowers pharmaceutical companies and leading research institutions to enhance disease understanding and accelerate biomarker discovery.\n\n\"Our enhanced SomaScan platform, powered in part by the complementary KREX™ technology, represents another step forward in our ability to address the needs of biopharma and translational research,\" said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. \"Fitting squarely within our 'omics as a service offering, we're excited to offer customers expanded SomaScan functionality, enabling deeper insights and more impactful discoveries.\"\n\nStandard BioTools developed this service offering through its acquisition of Sengenics, an innovative functional proteomics company. The terms of the transaction were not disclosed.\n\n**About Standard BioTools Inc.**\n\nStandard BioTools, the parent company of SomaLogic, Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at [standardbio.com](https://www.standardbio.com/) or connect with us on X, Facebook®, LinkedIn, and YouTube™.\n\nFor Research Use Only. Not for use in diagnostic procedures.\n\nLimited Use Label License and other terms may apply: [standardbio.com/legal/salesterms](https://www.standardbio.com/legal/salesterms). Patent and License Information: [standardbio.com/legal/notices](https://www.standardbio.com/legal/notices). Trademarks: [standardbio.com/legal/trademarks](https://www.standardbio.com/legal/trademarks). Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.\n\n**Forward-Looking Statements**\n\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the Company's expectations with respect to future performance and development of its technologies, the use of the Company's technologies to expand life sciences markets and research, and market and growth opportunity and potential. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the anticipated benefits and synergies of the merger and the integration of SomaLogic, Inc., including the potential for it to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from the merger with SomaLogic, Inc., including the anticipated decrease in operational expenses, at the levels it expects; possible integration, restructuring and transition-related disruption, including through the loss of customers, suppliers, and employees and adverse impacts on the Company's development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company's plans, or both; risks that the Company's expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company's business or external market conditions; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company's products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company's research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the \"Risk Factors\" section of the Company's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (\"SEC\") on March 1, 2024, and in the Company's other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.\n\n**Investor Contact**\n\nDavid HolmesGilmartin Group LLCir@standardbio.com\n\n**Media Contact**\n\nDan Moore / Tali EpsteinCollected StrategiesLAB-CS@collectedstrategies.com\n\n[**Print**](javascript:window.print\\(\\); \"Print Page\")\n\n[**Printed Materials** ](/printed-materials \"Printed Materials\")\n\n[**Email Alerts** ](/email-alerts \"Email Alerts\")\n\n[**Downloads** ](/download-library \"Downloads\")\n\n[**RSS** ](/rss-news-feeds \"RSS\")\n\n[**Search**](/search \"Search\")\n"
        },
        {
          "title": "Standard BioTools Appoints Alex Kim as Chief Financial Officer",
          "url": "https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-appoints-alex-kim-chief-financial-officer",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[Skip to Content](#skip-to-content)\n\n[![logo](/sites/g/files/knoqqb88461/themes/site/nir_pid1741/dist/images/logo-10-22.png)](https://www.standardbio.com/)\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News & Events](/press-releases)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/quarterly-results)\n    * [Quarterly Results](/financial-information/quarterly-results)\n    * [Annual Reports](/annual-reports)\n    * [SEC Filings](/sec-filings)\n  * [Stock Information](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Investment Calculator](/stock-information/investment-calculator)\n    * [Analyst Coverage](/analyst-coverage)\n    * [Key Ratios](/key-ratios)\n  * [Governance](/corporate-governance/governance-overview)\n    * [Governance Overview](/corporate-governance/governance-overview)\n    * [Management](https://www.standardbio.com/about/management)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Committee Composition](/corporate-governance/committeecomposition)\n    * [Contact the Board](/corporate-governance/contact-bod)\n    * [Social Responsibility](/social-responsibility)\n  * [Investor Resources](/investor-faqs)\n    * [Investor FAQs](/investor-faqs)\n    * [Investor Kit](/investor-kit-0)\n    * [Contact Us](/contact-investor)\n    * [Email Alerts](/email-alerts)\n\n\n\n# News Release Details\n\n# \n\nStandard BioTools Appoints Alex Kim as Chief Financial Officer\n\nNov 7, 2024\n\n[PDF Version](/node/19696/pdf)\n\nSOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization.\n\nMichael Egholm, President and Chief Executive Officer of Standard BioTools, said, “I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex’s deep understanding of our business make him the clear choice for the role and he will continue to be a key architect in the design and implementation of our strategic and financial plans moving forward.”\n\nPrior to joining Standard BioTools, Kim was President of Milliken’s Healthcare Division, initially joining the company in 2015 as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation and prior to that from 2002 to 2012, Kim worked at Danaher Corporation in a variety of roles across general management, M&A and business development. Over his career, Kim has completed over 40 transactions, largely focused on healthcare, medical technology and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business.\n\nKim said, “I am delighted to assume the CFO position and continue working alongside Michael and our talented team as we execute the Standard BioTools vision. We have strong momentum and we are moving forward with steadfast focus on operational excellence to achieve our financial targets and long-term growth objectives.”\n\nIn connection with this appointment, Jonathan Mickelsen, Standard BioTools’ Vice President and Corporate Controller, has been appointed as the Company’s Vice President & Chief Accounting Officer.\n\n**About Standard BioTools Inc.**\n\nStandard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at [standardbio.com](http://standardbio.com) or connect with us on X, Facebook®, LinkedIn, and YouTube™.\n\nFor Research Use Only. Not for use in diagnostic procedures.\n\nLimited Use Label License and other terms may apply: [standardbio.com/legal/salesterms](http://standardbio.com/legal/salesterms). Patent and License Information: [standardbio.com/legal/notices](http://standardbio.com/legal/notices).Trademarks: [standardbio.com/legal/trademarks](http://standardbio.com/legal/trademarks). Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.\n\n**Investor Contact:**\n\nDavid HolmesGilmartin Group LLC(332) 330-1031[ir@standardbio.com](https://www.globenewswire.com/Tracker?data=WXqtjf4z0AcFdSsRRDz4ziD1xdFSjcjADjWKPu1Ayo_FdX2tSgdjAWguVODlp70hGBa0NjzNBML3MLBVm6wWKKJciafvpkeZwZ3XwM3yqjVfd2nvIN7JcUw2h0kWhOngXrTQ0lkNzbt8dLczSkyn56K8h5Qc3CvUrXaIxH1XlTmr_mqmbplSO38hq5TSpFfUDFbYeIIX_hc3UwBlikG7RrIoUjxfe2uQJ73QOUWWbL_nQTq5qY4jd3nrZH1kY-zavXgPcxd2xmueRsOZQWGyRZbetOWhpImH9BGq72n0_FGuD1aHF7WY0aXq5AeCWnkUl3visrsipqvFDRcGDZpYNw6FLM_Um4HN08ZpJrm97GHNe7XdPsZiy6Fu84l8aoWCI9kk-A5FpR8gBAuBYdDFtAL0Q5mmKB89s4UE8HeUEbohU9DGsVODBu6isr9e5Bh4p7GlJAA2wiNY_0TQ-wCb9uTeWkKstuzRoOngWTntuiJQZgbw9KpXPSns4hiJ8OK6nX_LVE3H3FAFF1IkHAPcduj9MHNGXCirz4ICv5pi1Qo=)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2OTA5OSM2NTcwMTM2IzIwMDM4MTg=)![](https://ml.globenewswire.com/media/NDI0NDViNmYtZTVhZi00ODViLWE4MTEtZGViYzY2OGYyMzRhLTEwMTUzOTE=/tiny/Standard-BioTools-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/122934c3-b763-4386-89d1-3047d0704c17/small/sbt-new-august-2022-logo.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/122934c3-b763-4386-89d1-3047d0704c17)\n\nSource: Standard BioTools Inc.\n\n[**Print**](javascript:window.print\\(\\); \"Print Page\")\n\n[**Printed Materials** ](/printed-materials \"Printed Materials\")\n\n[**Email Alerts** ](/email-alerts \"Email Alerts\")\n\n[**Downloads** ](/download-library \"Downloads\")\n\n[**RSS** ](/rss-news-feeds \"RSS\")\n\n[**Search**](/search \"Search\")\n"
        },
        {
          "title": "Standard BioTools to Participate in Upcoming Investor Conferences",
          "url": "https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-participate-upcoming-investor-conferences-4",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[Skip to Content](#skip-to-content)\n\n[![logo](/sites/g/files/knoqqb88461/themes/site/nir_pid1741/dist/images/logo-10-22.png)](https://www.standardbio.com/)\n\n  * [Overview](/ \"Main Investor Relations Page\")\n  * [News & Events](/press-releases)\n    * [Press Releases](/press-releases)\n    * [Events & Presentations](/events-presentations)\n  * [Financials](/financial-information/quarterly-results)\n    * [Quarterly Results](/financial-information/quarterly-results)\n    * [Annual Reports](/annual-reports)\n    * [SEC Filings](/sec-filings)\n  * [Stock Information](/stock-information/stock-quote-chart)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Historic Stock Lookup](/stock-information/historic-stock-lookup)\n    * [Investment Calculator](/stock-information/investment-calculator)\n    * [Analyst Coverage](/analyst-coverage)\n    * [Key Ratios](/key-ratios)\n  * [Governance](/corporate-governance/governance-overview)\n    * [Governance Overview](/corporate-governance/governance-overview)\n    * [Management](https://www.standardbio.com/about/management)\n    * [Board of Directors](/corporate-governance/board-of-directors)\n    * [Committee Composition](/corporate-governance/committeecomposition)\n    * [Contact the Board](/corporate-governance/contact-bod)\n    * [Social Responsibility](/social-responsibility)\n  * [Investor Resources](/investor-faqs)\n    * [Investor FAQs](/investor-faqs)\n    * [Investor Kit](/investor-kit-0)\n    * [Contact Us](/contact-investor)\n    * [Email Alerts](/email-alerts)\n\n\n\n# News Release Details\n\n# \n\nStandard BioTools to Participate in Upcoming Investor Conferences\n\nOct 31, 2024\n\n[PDF Version](/node/19681/pdf)\n\nSOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November:\n\n  * **UBS Global Healthcare Conference on November 12**th**, 2024** President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PT\n  * **Jefferies London Healthcare Conference on November 19**th**– 21** st**, 2024** President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 19, 2024, at 8:30 a.m. GMT\n\n\n\nAvailable presentations will be webcast live and available on the Investor Relations page of the Company’s website at [Events & Presentations](https://www.globenewswire.com/Tracker?data=OiAAqAhVUHKPahKFjSwEgOjy5blO2gm5ditAZWBtry-PlgxmQHncfuhIlzlpgJ0yV96KsYwwEGUDZc1aQc9bw-iSXR3JJGmaxwZIF_9WY-HelXggNy4xxq6GLzyP9Ywc3MNfCy6ZZ9vSWHrmyds-YA==). A recording will be archived and available on the Standard BioTools Investor Relations page at [investors.standardbio.com](https://www.globenewswire.com/Tracker?data=5tpiPXndTxXayLWG7OhhOxXPKtoOZYQRAgHzYiK4d5KJ2kRKl9z9XgMVOsD9RvOCi14V-tovDv_x7LCfbJMX_0zjg44tiaFEx-2j-HDxCtFz7dKfUtqI9jVpstvcDycG).\n\n**About Standard BioTools Inc.**\n\nStandard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at [standardbio.com](https://www.globenewswire.com/Tracker?data=xH2vcdDfgN8OnlMSgrkzc13l0MbwSSvGo2f3CwTX0XVcDO6VjG5PjswgkgGOhOYpdAnvf2tehisVihutu022UhHQHdsfBhmnWh89AHdlT1w=) or connect with us on X, Facebook®, LinkedIn, and YouTube™.\n\nFor Research Use Only. Not for use in diagnostic procedures.\n\nLimited Use Label License and other terms may apply: [standardbio.com/legal/salesterms](https://www.globenewswire.com/Tracker?data=xH2vcdDfgN8OnlMSgrkzc3NwXISzY4jFZ9JHhgACBFuXFAXie33waw97jnR6DDnwwYYYHHBWBYdNrGH8qKVlLmHGrKoYZme_biokhxN3XX3D1tWmvESPBJgkPRxPZlpFOFBel8_oTbv30bxQhY8fFg==).Patent and License Information: [standardbio.com/legal/notices](https://www.globenewswire.com/Tracker?data=xH2vcdDfgN8OnlMSgrkzc3NwXISzY4jFZ9JHhgACBFvzX7h93LsyJLh5PJvz-JwocjJ0ErRvJJLOfvg74PmnreozI70uGRXCwxAGSU3HyljPtwSGv7LwDXW3UujwsuAs). Trademarks: [standardbio.com/legal/trademarks](https://www.globenewswire.com/Tracker?data=xH2vcdDfgN8OnlMSgrkzc3NwXISzY4jFZ9JHhgACBFu4PThxniSdQSyBHBfwZaeaS_i7fLavDmeZH-d1qV3Lw2IEc_UyHwxRDGyrgjsNA4gv4WZ81opux0UwHlEL0xtB2s2STBSvMhedjOBZEg3Txg==). Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.\n\n**Investor Contact**\n\nDavid HolmesGilmartin Group LLC[ir@standardbio.com](https://www.globenewswire.com/Tracker?data=Tu14DxGxDdLMNR7h-Rag3t5oVaxcBdWBBrZVK7SpdvHVPN0W7izifZvKJOPU2QBm-pj4ELLcXkvrcvgCHswIlsVr2PXm3nKHK5_zsHt3VMg=)\n\n![](https://www.globenewswire.com/newsroom/ti?nf=OTI2NTEwMCM2NTU4NTAxIzIwMDM4MTg=)![](https://ml.globenewswire.com/media/NTg3ZTU3NzQtMDI3YS00ZDJiLThlYjctMWUwMWE0ZGIzMTRiLTEwMTUzOTE=/tiny/Standard-BioTools-Inc-.png)\n\n[![Primary Logo](https://ml.globenewswire.com/media/122934c3-b763-4386-89d1-3047d0704c17/small/sbt-new-august-2022-logo.png)](https://www.globenewswire.com/NewsRoom/AttachmentNg/122934c3-b763-4386-89d1-3047d0704c17)\n\nSource: Standard BioTools Inc.\n\n[**Print**](javascript:window.print\\(\\); \"Print Page\")\n\n[**Printed Materials** ](/printed-materials \"Printed Materials\")\n\n[**Email Alerts** ](/email-alerts \"Email Alerts\")\n\n[**Downloads** ](/download-library \"Downloads\")\n\n[**RSS** ](/rss-news-feeds \"RSS\")\n\n[**Search**](/search \"Search\")\n"
        }
      ]
    },
    {
      "section_name": "Events & Presentations",
      "links": [
        {
          "title": "Jefferies London Healthcare Conference 2024",
          "url": "https://wsw.com/webcast/jeff315/register.aspx?conf=jeff315&page=lab&url=https%3A//wsw.com/webcast/jeff315/lab/1666476",
          "content": "![Jefferies](/images/resources/jefferies20120920/images/mm_logo.png)\n\n  * [CONFERENCES](https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159)\n  * [JEFFERIES HOME](https://www.jefferies.com/)\n\n\n\n# Jefferies London Healthcare Conference\n\n## November 19th - 21st, 2024\n\nTo register for the webcast, please enter your information in the form below.\n\nEvent: |  Jefferies London Healthcare Conference  \n---|---  \nPresentation: |  Standard BioTools  \nTime: |  11/19/2024 8:30 AM (GMT)  \n  \nFirst Name* |  First name required  \n---|---  \nLast Name* |  First and last name cannot be the same. Last name required  \nCompany Name* |  Company name required  \nEmail* |  Email required Email is not valid  \n* Required Field  \n  \nYou must have cookies enabled in order to register for this event\n\n[![Summitcast](/images/resources/images/summitcast_logo_sm_black.png)](https://twstevents.com/divisions/summitcast)\n"
        },
        {
          "title": "UBS Global Healthcare Conference",
          "url": "https://event.webcasts.com/starthere.jsp?ei=1694378&tp_key=815ee76ef0&tp_special=8",
          "content": "![](https://cache.webcasts.com/content/conf001/1694378/content/815ee76ef0a18e4b9f95f571c661fe8706afbd43/banner/UBS.png)\n\nComplete this form to enter the webcast. \n\n(* indicates required field)\n\n## Complete this form to enter the webcast.  (* indicates required field)\n\nFirst Name*: Last Name*: Company*: Email*:\n\n## Tue, Nov 12, 2024 1:14 PM PST (Wed, Nov 13, 2024 2:44 AM Asia/Calcutta) \n\n**Standard BioTools**\n\nfrom the\n\nGlobal Healthcare\n\nConference\n\n[FAQs and System Test](#)\n\n[![Webcast by GlobalMeet](/viewer/images/webcastbygm.png)](https://www.globalmeet.com)\n\n  * [Outlook ❯](#)\n  * [Google ❯](#)\n\n\n"
        },
        {
          "title": "Standard BioTools Inc. Third Quarter 2024 Financial Results",
          "url": "https://edge.media-server.com/mmc/p/upxgn3hj",
          "content": "Settings \n"
        }
      ]
    },
    {
      "section_name": "Latest Reports",
      "links": [
        {
          "title": "Q3 2024 Financial Results Slides",
          "url": "https://investors.standardbio.com/static-files/1229014c-2e8e-4a98-b6b4-c35aac347a9f",
          "content": "\n"
        },
        {
          "title": "Environmental, Social, and Governance Report",
          "url": "https://investors.standardbio.com/static-files/a2cbf496-7561-4c29-9ac4-5f9a3be4acad",
          "content": "\n"
        }
      ]
    }
  ]
}